U.S. Stock News

NYSE:NET
NYSE:NETIT

Cloudflare (NET) Revenue Momentum Tests Rich Valuation Narrative After Q4 Loss Continues

Cloudflare FY 2025 earnings: revenue momentum meets persistent losses Cloudflare (NET) has wrapped up FY 2025 with Q4 revenue of US$614.5 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$12.1 million loss. The latest trailing twelve month figures show revenue of US$2.0 billion and a basic EPS loss of US$0.30. Over recent periods, the company has seen quarterly revenue move from US$459.9 million in Q4 2024 to US$614.5 million in Q4 2025. Basic EPS...
NYSE:D
NYSE:DIntegrated Utilities

Is Dominion’s Infrastructure Modernization And Clean-Energy Pivot Altering The Investment Case For Dominion Energy (D)?

Recently, Dominion Energy has been ramping up investments to modernize its electric and natural gas infrastructure while redirecting capital toward cleaner energy projects, aiming to strengthen its core regulated utility operations. This shift underscores how Dominion is trying to balance long-term energy transition priorities with the steady, regulated cash flows and dividend profile that many income-focused investors look for. We’ll now examine how Dominion’s push into cleaner, modernized...
NasdaqGS:CMCSA
NasdaqGS:CMCSATelecom

Comcast Spin Off Of Versant Media Reshapes Media Exposure And Valuation

Comcast, ticker NasdaqGS:CMCSA, has completed the spin off of Versant Media Group into an independent company. The deal moves key media and digital brands out of Comcast’s portfolio and into Versant Media Group. The separation affects both Comcast and Versant shareholders by reshaping ownership of these media assets. For you as an investor, this move changes what sits inside NasdaqGS:CMCSA. Comcast now leans more on its remaining media, broadband and connectivity businesses, while Versant...
NYSE:SOLV
NYSE:SOLVMedical Equipment

Solventum Expands MedSurg With Acera Deal As Valuation Signals Upside

Solventum (NYSE:SOLV) has completed its acquisition of Acera Surgical, a bioscience company focused on regenerative wound care. The deal expands Solventum's MedSurg portfolio and adds exposure to regenerative medicine applications in US acute care settings. The company expects the transaction to have a long term accretive impact. For you as an investor, this move puts more attention on Solventum's MedSurg business, which already plays a central role in hospital and surgical settings...